Anti-TRAF7 Antibody Picoband® fluoro550 Vervoeging

Tumor necrosis factor (TNF; see MIM 191160) receptor-associated factors, such as TRAF7, are signal transducers for members of the TNF receptor superfamily (see MIM 191190) . TRAFs are composed of an N-terminal cysteine/histidine-rich region containing zinc RING and/or zinc finger motifs; a coiled-coil (leucine zipper) motif; and a homologous region that defines the TRAF family, the TRAF domain, which is involved in self-association and receptor binding.

Long-chain-fatty-acid--CoA ligase 3;6.2.1.3; Long-chain acyl-CoA synthetase 3; LACS 3; ACSL3; ACS3, FACL3, LACS3

TRAF7

84231

Q6Q0C0

Human

No cross-reactivity with other proteins.

E.coli-derived human TRAF7 recombinant protein (Position: R29-C670) .

Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level) . Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor.

Flow Cytometry

Cardiovascular, Fatty Acid Oxidation, Fatty Acids, Lipid and Lipoprotein Metabolism, Lipid Metabolism, Lipids/Lipoproteins, Metabolic Signaling Pathways, Metabolism, Pathways and Processes, Redox Metabolism, Signal Transduction

Immunogen affinity purified.

Liquid

Acyl-CoA synthetases (ACSL) activates long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. ACSL3 mediates hepatic lipogenesis (By similarity) . Preferentially uses myristate, laurate, arachidonate and eicosapentaenoate as substrates (By similarity) . Has mainly an anabolic role in energy metabolism. Required for the incorporation of fatty acids into phosphatidylcholine, the major phospholipid located on the surface of VLDL (very low density lipoproteins) . .

1. Bouwmeester, T., Bauch, A., Ruffner, H., Angrand, P.-O., Bergamini, G., Croughton, K., Cruciat, C., Eberhard, D., Gagneur, J., Ghidelli, S., Hopf, C., Huhse, B., and 16 others. A physical and functional map of the human TNF-alpha/NF-kappa-B signal transduction pathway. Nature Cell Biol. 6: 97-105, 2004. Note: Erratum: Nature Cell Biol. 6: 465 only, 2004. 2. Krumm, N., Turner, T. N., Baker, C., Vives, L., Mohajeri, K., Witherspoon, K., Raja, A., Coe, B. P., Stessman, H. A., He, Z.-X., Leal, S. M., Bernier, R., Eichler, E. E. Excess of rare, inherited truncating mutations in autism. Nature Genet. 47: 582-588, 2015. 3. Tokita, M. J., Chen, C.-A., Chitayat, D., Macnamara, E., Rosenfeld, J. A., Hanchard, N., Lewis, A. M., Brown, C. W., Marom, R., Shao, Y., Novacic, D., Wolfe, L., and 25 others. De novo missense variants in TRAF7 cause developmental delay, congenital anomalies, and dysmorphic features. Am. J. Hum. Genet. 103: 154-162, 2018.

At -20 ̊C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

80420 MW

6

Long-chain-fatty-acid--CoA ligase 3

Mitochondrion outer membrane ; Single-pass type III membrane protein . Peroxisome membrane ; Single-pass type III membrane protein . Microsome membrane ; Single-pass type III membrane protein . Endoplasmic reticulum membrane ; Single-pass type III membrane protein .

Long-chain-fatty-acid--CoA ligase 3

Rabbit IgG

Each vial contains 50% glycerol, 0.9% NaCl, 0.2% Na2HPO4, 0.02% NaN3.